TITLE

Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study

AUTHOR(S)
Jason A. Roberts; Rob Boots; Claire M. Rickard; Peter Thomas; Jo Quinn; Darren M. Roberts; Brent Richards; Jeffrey Lipman
PUB. DATE
February 2007
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Feb2007, Vol. 59 Issue 2, p285
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: To compare the clinical and bacteriological outcome of critically ill patients with sepsis treated by ceftriaxone administered as a once-a-day intermittent bolus dose or by 24 h continuous infusion. Patients and methods: We conducted an open-label, randomized controlled pilot study in 57 patients clinically diagnosed with sepsis (suspected/proven infection and systemic inflammatory response syndrome) in a tertiary level intensive care unit. Patients were randomized to receive 2 g of ceftriaxone administered by once-daily intermittent bolus dosing or by 24 h continuous infusion. Clinical and bacteriological outcomes were assessed by blinded clinicians. Results: Fifty-seven patients were enrolled in the study, 50 of whom fulfilled the a priori definition of treatment for 4 or more days. The infusion (n = 29) and bolus groups (n = 28) were similar in terms of demographics, although the median age of those receiving the infusion was younger. Intention-to-treat analysis found no statistically significant differences in the primary outcomes for clinical response (P = 0.17), clinical cure [infusion n = 13/29 versus bolus n = 5/28; adjusted odds ratio (AOR) = 3.74; 95% confidence interval (95% CI) = 1.11–12.57; P = 0.06], bacteriological response (P = 0.41) and bacteriological cure (infusion n = 18/29 versus bolus 14/28; AOR = 1.64; 95% CI = 0.57–4.70; P = 0.52). However, logistic regression in patients that complied with the a priori definitions who received ceftriaxone by continuous infusion (AOR = 22.8; 95% CI = 2.24–232.3; P = 0.008) or patients with a low Acute Physiology and Chronic Health Evaluation (APACHE) II score (AOR = 0.70; 95% CI = 0.54–0.91; P = 0.008) were associated with an improved clinical outcome when age and Sepsis Organ Failure Assessment (SOFA) score at time of study entry were controlled for. Conclusions: This pilot study suggests clinical and bacteriological advantages of continuous infusion of ceftriaxone over bolus administration in critically ill patients in patients requiring 4 or more days of treatment. This sets the scene for a large multicentre double-blind randomized controlled trial to confirm these findings.
ACCESSION #
24848287

 

Related Articles

  • Sequential evaluation of prognostic models in the early diagnosis of acute kidney injury in the intensive care unit. e Silva, Verônica Torres Costa; de Castro, Isac; Liaño, Fernando; Muriel, Alfonso; Rodríguez-Palomares, Jose R.; Yu, Luis // Kidney International;May2009, Vol. 75 Issue 9, p982 

    General and specific severity scores for patients with acute kidney injury have significant limitations due in part to the diversity of methods that have been used. Here we prospectively validated five general (APACHE II, SAPS II, SOFA, LODS, and OSF) and three specific (SHARF, Liaño, and...

  • Central venous blood culture: a useful test for catheter colonisation? Juste, R. N.; Hannan, M.; Glendenning, A.; Azadian, B.; Soni, N. // Intensive Care Medicine;Sep2000, Vol. 26 Issue 9, p1373 

    Objective: To evaluate the widespread practice of using qualitative culture of venous blood taken through central venous catheters (CVCs) as a means of diagnosing catheter colonisation in situ.Design: A prospective clinical study.Patients: Three hundred...

  • Procalcitonin as a marker of the systemic inflammatory response to infection. Reinhart, K.; Karzai, W.; Meisner, M. // Intensive Care Medicine;Sep2000, Vol. 26 Issue 9, p1193 

    Examines the use of procalcitonin as a possible marker of the systemic inflammatory response to infection. Biology of procalcitonin; Relation between the increase in procalcitonin levels and severity of inflammatory response to infection; Usability of procalcitonin in identifying an infectious...

  • Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Masson, Serge; Caironi, Pietro; Spanuth, Eberhard; Thomae, Ralf; Panigada, Mauro; Sangiorgi, Gabriela; Fumagalli, Roberto; Mauri, Tommaso; Isgrò, Stefano; Fanizza, Caterina; Romero, Marilena; Tognoni, Gianni; Latini, Roberto; Gattinoni, Luciano // Critical Care;2014, Vol. 18 Issue 1, p1 

    Introduction Sepsis, a leading cause of death in critically ill patients, is the result of complex interactions between the infecting microorganisms and the host responses that influence clinical outcomes. We evaluated the prognostic value of presepsin (sCD14-ST), a novel biomarker of bacterial...

  • An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence In Acutely Ill Patients (SOAP) study. Sprung, Charles L.; Sakr, Yasser; Vincent, Jean-Louis; Le Gall, Jean-Roger; Reinhart, Konrad; Ranieri, V. Marco; Gerlach, Herwig; Fielden, Jonathan; Groba, C. B.; Payen, Didier // Intensive Care Medicine;Mar2006, Vol. 32 Issue 3, p421 

    Objective: To define the frequency and prognostic implications of SIRS criteria in critically ill patients hospitalized in European ICUs.Design and Setting: Cohort, multicentre, observational study of 198 ICUs in 24 European countries.Patients and Interventions:...

  • Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Alberti, Corinne; Brun-Buisson, Christian; Burchardi, Hilmar; Martin, Claudio; Goodman, Sergey; Artigas, Antonio; Sicignano, Alberto; Palazzo, Mark; Moreno, Rui; Boulmé, Ronan; Lepage, Eric; Le Gall, Jean Roger // Intensive Care Medicine;Feb2002, Vol. 28 Issue 2, p108 

    Objectives: To examine the incidence of infections and to describe them and their outcome in intensive care unit (ICU) patients. Design and setting: International prospective cohort study in which all patients admitted to the 28 participating units in eight countries between May 1997 and May...

  • Other supportive therapies in sepsis. Pérez, Javier; Dellinger, R. Phillip // Intensive Care Medicine;Feb2001 Supplement 1, Vol. 27, pS116 

    Discusses supportive therapies for patients with sepsis. Importance of nutritional support in supporting the critically ill septic patient who is unable to eat; Impact of sepsis and the associated organ dysfunction on the patient's risk for development of stress ulcers.

  • Parenteral glutamine increases serum heat shock protein 70 in critically ill patients. Ziegler, Thomas; Ogden, Lorraine G.; Singleton, Kristen D.; Menghua Luo; Fernandez-Estivariz, Concepcion; Griffith, Daniel P.; Galloway, John R.; Wischmeyer, Paul E.; Ziegler, Thomas R; Luo, Menghua // Intensive Care Medicine;Aug2005, Vol. 31 Issue 8, p1079 

    Objective: Heat shock protein 70 (HSP-70) is protective against cellular and tissue injury. Increased serum HSP-70 levels are associated with decreased mortality in trauma patients. Glutamine (Gln) administration increases serum and tissue HSP-70 expression in experimental models of...

  • Jaundice in critical illness: promoting factors of a concealed reality. Brienza, Nicola; Dalfino, Lidia; Cinnella, Gilda; Diele, Caterina; Bruno, Francesco; Fiore, Tommaso // Intensive Care Medicine;Feb2006, Vol. 32 Issue 2, p267 

    Objective: In critical illness, liver dysfunction (LD) is associated with a poor outcome independently of other organ dysfunctions. Since strategies to support liver function are not available, a timely and accurate identification of factors promoting LD may lead to prevention or...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics